Answers are grounded in this paper and cite their sources.
Evaluates AM-PAC mobility score impact on mortality in liver transplant patients, suggesting its practical use for patient risk assessment.
BACKGROUND: Functional status and mobility are well-established predictors of liver transplant (LT) outcomes when measured in the ambulatory setting, but are less well studied in the inpatient setting. The Activity Measure for Postacute Care "6-Clicks" Basic Mobility (AM-PAC) score is a rapid, validated mobility assessment tool for hospitalized patients. METHODS: Adult patients with cirrhosis listed for transplant at a single center with a pre-LT hospitalization (2015-2024) were included. All pre-LT AM-PAC scores (range, 6-24; with 6 = severe impairment) were extracted from inpatient encounters. AM-PAC cut points were identified by optimizing model fit (pseudo-log-likelihood) in multivariable competing-risks regression models for waitlist mortality (WLM; death or delisting due to illness). Cox regression assessed risk of post-LT mortality. RESULTS: Among 465 patients with cirrhosis, median (interquartile range) Model for End-Stage Liver Disease score on admission was 25 (19-31); 21% of patients experienced WLM and 67% underwent LT. Optimizing model fit yielded AM-PAC cut points of 15 and 23, stratifying patients into low- (34%), intermediate- (55%), and high-risk (11%) groups. On multivariable analysis, adjusting for Model for End-Stage Liver Disease score, both intermediate-risk (scores 16-23; subdistribution hazard ratio [SHR], 2.01; 95% confidence interval [CI], 1.10-3.69) and high-risk (scores 6-15; SHR, 5.11; 95% CI, 2.20-11.89) groups were associated with WLM. Among patients who underwent LT (n = 301), each point decrease in the final pretransplant AM-PAC score was associated with a 15% increase in post-LT mortality (HR, 1.15; 95% CI, 1.04-1.28). CONCLUSIONS: Inpatient mobility, as measured by AM-PAC score, is strongly associated with both waitlist and post-LT mortality. As it is already embedded in inpatient workflows and rapidly administered, the AM-PAC tool offers a practical, scalable approach to risk stratify LT patients.
No takes yet. Share an insight, caveat, or question.
Calthorpe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: